TARDBP and amyotrophic lateral sclerosis: Histological assessment of a subset of ALS cases (n = 6) from these trials recently concluded that CuII(atsm) treatment had no significant pathological benefit [76], despite CuII(atsm) treatment associating with a > 80% decrease in neuronal TDP-43 pathology in motor cortex and spinal cord (p = 0.1 and p = 0.2, respectively) and significantly diminishing microglial activation in spinal cord by 64% [77].